

REMARKS

Status

Upon entry of the amendments, Claims 1-10, 13-14 and 24-43 will be pending in this application. Support for the amendments and new claims can be found in the original claims and throughout the specification. No new matter will be been added upon entry of this amendment.

Restriction

The Examiner has required restriction in the above-identified application and has divided the claims into seven groups as described in the Office Action. Applicants have elected, with partial traverse, Group I, for examination purposes only.

The present amendment limits the claims to the compounds defined in Group I, with exceptions to the definition of R⁵ being H or alkyl, to expedite prosecution of the present application. Applicants respectfully submit that there is no divergence between H and alkyl. Further, there is no serious burden placed on the Examiner with all the limitations defined for other groups by the Examiner as described in Group I. Therefore, Applicants request Examiner's reconsideration of the definition of R⁵ and extend the search to include R⁵ being H.

The indication of allowed subject matter and rejoining Group I and Group IV is acknowledged with appreciation.

Applicants respectfully traverse the restriction between Group I (Claims 1-7) and Group V (Claims 11-12) on the grounds that no materially different product has been shown for which process can be practiced. Applicants respectfully request that Group V (Claims 11-12) be rejoined once the subject matter of Claims 1-6 has been determined to be allowable. Process Claims 11-12 include all of the limitations of product Claims 1-6. Their rejoinder, therefore, will be proper under MPEP 821.04.

112 Rejections

Claim 10 is rejected under 35 U.S.C. 112, 2nd paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Office Action states that "(f) other procedures in which


**DOCKET NO.: PH 7493 NP
10/796,396**

blood is exposed to an artificial surface that promotes thrombosis" is unclear since it does not clearly define what these "other procedures" are. Applicants respectfully traverse the rejection. These other procedures are well defined by the phrase - "in which blood is exposed to an artificial surface that promotes thrombosis". One skilled in the art can easily recognize such procedures. Therefore, Claim 10 is not indefinite. Withdrawal of this rejection is respectfully requested.

In view of the foregoing, Applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Respectfully submitted,

Date: June 8, 2005



Jing G. Sun, Ph.D.
Agent for Applicants
Registration No. 45,914

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791 (phone)
(609) 252-4526 (fax)